Gentium S.p.a. Negative on Defibrotide, Shares Plunged - 4.37 (36.63%) @ 10:01 Am Et

Gentium S.p.A. announced today that, the Company had presented an oral explanation at the European Medicines Agency's Committee for Medicinal Products for Human Use as part of its Marketing Authorization Application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell ... (more)

http://www.biospace.com/news_story.aspx?StoryID=288255&full=1